5 Star
.
4.29%
  • .
    .
    .
    http://game-rapidshare.com/Hoque-mother-of-Talcott-from-Ayodhya?Lillywhite=209

    Baumhefner said for many patients with breakthrough disease on standard IFNβ-1a, increasing the treatment dosage with twice-weekly therapy may be an acceptable alternative to switching treatments.

    June Halper, MSN, MSCN, CMCS CEO, agreed, noting that "it makes a lot of sense for some patients to stay on a drug that has worked for them, and tweak the therapy if there is a breakthrough instead of automatically moving on to another drug," she told MedPage Today.

    Baumhefner said a prospective, blinded, randomized trial comparing once-weekly and twice-weekly intramuscular IFNβ-1a may be warranted.

    .